News | July 03, 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
Positive opinions based on significant survival benefit
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
Subscribe To Our Newsletter & Stay Updated
